Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 35, Issue 4, Pages 207–212
http://dx.doi.org/10.1155/2013/761537
Clinical Study

AGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients

1Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic
2Department of Pathology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic
3Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic

Received 7 June 2013; Revised 14 August 2013; Accepted 16 August 2013

Academic Editor: Sheng Pan

Copyright © 2013 Roman Hrstka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” Ca: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005. View at Google Scholar · View at Scopus
  2. B. S. Katzenellenbogen and J. Frasor, “Therapeutic targeting in the estrogen receptor hormonal pathway,” Seminars in Oncology, vol. 31, no. 1, pp. 28–38, 2004. View at Google Scholar · View at Scopus
  3. J. F. R. Robertson, P. M. Cannon, R. I. Nicholson, and R. W. Blamey, “Oestrogen and progesterone receptors as prognostic variables in hormonally treated breast cancer,” International Journal of Biological Markers, vol. 11, no. 1, pp. 29–35, 1996. View at Google Scholar · View at Scopus
  4. R. Hrstka, R. Nenutil, A. Fourtouna et al., “The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers,” Oncogene, vol. 29, no. 34, pp. 4838–4847, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. H. E. Innes, D. Liu, R. Barraclough et al., “Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients,” British Journal of Cancer, vol. 94, no. 7, pp. 1057–1065, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. D. A. Thompson and R. J. Weigel, “hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines,” Biochemical and Biophysical Research Communications, vol. 251, no. 1, pp. 111–116, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Pohler, A. L. Craig, J. Cotton et al., “The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage,” Molecular and Cellular Proteomics, vol. 3, no. 6, pp. 534–547, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Liu, P. S. Rudland, D. R. Sibson, A. Platt-Higgins, and R. Barraclough, “Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas,” Cancer Research, vol. 65, no. 9, pp. 3796–3805, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. Z. Wang, Y. Hao, and A. W. Lowe, “The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation,” Cancer Research, vol. 68, no. 2, pp. 492–497, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. M. Hengel, E. Murray, S. Langdon et al., “Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance,” Journal of Proteome Research, vol. 10, no. 10, pp. 4567–4578, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. D. M. Abd El-Rehim, G. Ball, S. E. Finder et al., “High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses,” International Journal of Cancer, vol. 116, no. 3, pp. 340–350, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. K. S. McCarty Jr., L. S. Miller, E. B. Cox, J. Konrath, and K. S. McCarty Sr., “Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies,” Archives of Pathology and Laboratory Medicine, vol. 109, no. 8, pp. 716–721, 1985. View at Google Scholar · View at Scopus
  13. L. C. Hodges, J. D. Cook, E. K. Lobenhofer et al., “Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells,” Molecular Cancer Research, vol. 1, no. 4, pp. 300–311, 2003. View at Google Scholar · View at Scopus
  14. G. Arpino, S. J. Green, D. C. Allred et al., “HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study,” Clinical Cancer Research, vol. 10, no. 17, pp. 5670–5676, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Dong, A. Gupta, R. K. Pai, M. Tun, and A. W. Lowe, “The human adenocarcinoma-associated gene, AGR2, induces expression of Amphiregulin through hippo pathway co-activator YAP1 activation,” The Journal of Biological Chemistry, vol. 286, no. 20, pp. 18301–18310, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Hrstka, E. Murray, V. Brychtova, P. Fabian, T. R. Hupp, and B. Vojtesek, “Identification of an AKT-dependent signalling pathway that mediates tamoxifen-dependent induction of the pro-metastatic protein anterior gradient-2,” Cancer Letters, vol. 333, pp. 187–193, 2013. View at Google Scholar